# CYCLONE 3 (abemaciclib): what clinicians are saying

> 218 statements from 15 sources (4 podcasts, 1 video, 9 posts, 1 registry record), 54 of them from 11 confirmed clinicians, each linked to its source. Commentary checked Nov 17, 2026.

## Report

- Trial: CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
- NCT ID: NCT05288166
- Registry: https://clinicaltrials.gov/study/NCT05288166
- Sponsor: Eli Lilly and Company
- Phase: Phase 3
- Status: Active, not recruiting
- Drugs tested: abemaciclib plus abiraterone
- Indication: high-risk metastatic hormone-sensitive prostate cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-17 UTC
- Last checked: 2026-11-17 UTC
- Release hash: 92ea8f640bfc4e3e319463c5000c1c8774c959c9b72f58e5461219d903f8ac0b

## Counts

- Commentary sources screened: 41
- Sources cited by verified statements: 15
- Verified statements: 218
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 54
- Findings: 11
- Named people in screened sources (unnamed speakers and accounts not counted): 14
- Speakers cited: 14
- Cited speakers with a verified identity: 13
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 11
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 11
- By role and specialty (the abstract's specialty counts):
  - 6 physician, Medical oncology
  - 3 physician, specialty not confirmed
  - 1 physician, Surgical oncology
  - 1 physician, Urology
- Organisational or shared accounts (not counted as people): 2

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

For CYCLONE 3, a medical oncologist considered benefit less likely after reporting a CYCLONE-2 setback in castration-resistant disease, but left the answer to trials then underway. Gastrointestinal effects and low blood counts were raised in one discussion without a risk–benefit verdict. The cited commentary does not address the posted results, leaving clinicians’ interpretation of those results unknown.

## Question clinicians left open

What do clinicians still need to see in CYCLONE 3 to establish whether adding abemaciclib to abiraterone translates the CDK4/6–androgen receptor rationale into clinical benefit in high-risk metastatic hormone-sensitive prostate cancer?

From finding F1 (12 statements from 2 speakers in 8 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. CDK4/6–AR rationale: why speakers see prostate cancer benefit as an open question
  - 12 statements from 2 speakers in 8 sources, 5 of them podcasts or videos.
  - 2 of the 2 named speakers in this finding hold this view.
  - 1 of the report's 11 cited clinicians.
- F2. CDK4/6 in prostate cancer: what speakers say
  - 2 statements in 2 sources, 1 of them a podcast or video.
  - No named clinician · accounts and unnamed speakers.
- F3. CYCLONE 3: what speakers say
  - 10 statements from 3 speakers in 6 sources, 3 of them podcasts or videos.
  - 1 of the report's 11 cited clinicians.

### Beyond the trial population

- F4. Triplets: what speakers say
  - 18 statements from 3 speakers in 3 sources, all podcasts or videos.
  - 3 of the report's 11 cited clinicians.
- F5. This lung-only relapse: what speakers say
  - 11 statements in 2 sources, 1 of them a podcast or video.
  - No named clinician · accounts and unnamed speakers.
- F6. MHSPC: most clinicians usually escalate when apt—one rarely holds ADT for harm
  - 11 statements from 3 speakers in 3 sources, all podcasts or videos.
  - 2 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of them holds its caveat, “one rarely holds ADT for harm”.
  - 3 of the report's 11 cited clinicians.
- F7. Hormonal partners: how clinicians weigh tolerability, comorbidity and cost
  - 19 statements from 2 speakers in 4 sources, all podcasts or videos.
  - 2 of the 2 named speakers in this finding hold this view, each a confirmed clinician.
  - 2 of the report's 11 cited clinicians.
- F8. Chemo-free darolutamide: a clinician seeks selective access—one awaits data
  - 7 statements from 2 speakers in 3 sources, all podcasts or videos.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “one awaits data”.
  - 2 of the report's 11 cited clinicians.
- F9. Genetic work-up: what speakers say
  - 23 statements from 5 speakers in 8 sources, 4 of them podcasts or videos.
  - 4 of the report's 11 cited clinicians.
- F10. PEACE-1 prostate RT: what speakers say
  - 15 statements from 3 speakers in 4 sources, 3 of them podcasts or videos.
  - 3 of the report's 11 cited clinicians.
- F11. Hard de novo doublet/triplet cases: a clinician weighs chance in a neuroendocrine rise
  - 13 statements from 2 speakers in 3 sources, all podcasts or videos.
  - 1 of the 2 named speakers in this finding holds this view, a confirmed clinician.
  - 2 of the report's 11 cited clinicians.

8 of the 11 findings and 114 of the 218 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 12 | 15 | 8 | 2 | 3 |
| F2 | 2 | 2 | 2 | 0 | 2 |
| F3 | 10 | 13 | 6 | 3 | 3 |
| F4 | 18 | 15 | 3 | 3 | 4 |
| F5 | 11 | 7 | 2 | 0 | 3 |
| F6 | 11 | 10 | 3 | 3 | 4 |
| F7 | 19 | 9 | 4 | 2 | 4 |
| F8 | 7 | 4 | 3 | 2 | 3 |
| F9 | 23 | 19 | 8 | 5 | 3 |
| F10 | 15 | 11 | 4 | 3 | 4 |
| F11 | 13 | 11 | 3 | 2 | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 8 | 3 | 0 | 0 | 1 | 12 | 8 | 2 posts and articles, 5 podcasts and video, 1 registry |
| F2 | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 1 podcast or video, 1 registry |
| F3 | 5 | 0 | 1 | 0 | 4 | 12 | 6 | 2 posts and articles, 3 podcasts and video, 1 registry |
| F4 | 10 | 4 | 2 | 1 | 1 | 20 | 3 | 3 podcasts and video |
| F5 | 4 | 2 | 3 | 0 | 2 | 13 | 4 | 1 podcast or video, 1 registry |
| F6 | 7 | 0 | 2 | 0 | 2 | 14 | 2 | 3 podcasts and video |
| F7 | 6 | 2 | 8 | 2 | 1 | 19 | 3 | 4 podcasts and video |
| F8 | 3 | 2 | 1 | 0 | 1 | 7 | 1 | 3 podcasts and video |
| F9 | 8 | 3 | 6 | 0 | 6 | 24 | 2 | 4 posts and articles, 4 podcasts and video |
| F10 | 9 | 2 | 3 | 0 | 1 | 15 | 2 | 3 podcasts and video, 1 registry |
| F11 | 6 | 2 | 2 | 0 | 3 | 13 | 1 | 3 podcasts and video |

### Trial dimensions

- Primary endpoint: Radiographic Progression-Free Survival (rPFS) Assessed by Investigator: F3 (2 shared claims)
- Secondary endpoints: F3 (1 shared claims)
- Population and setting: F1 (1 shared claims), F3 (2 shared claims)
- The comparison: F1 (1 shared claims), F3 (2 shared claims)
- Safety and tolerability: F2 (1 shared claims)
- Design and conduct: F3 (7 shared claims)

## Abbreviations

- ADT: androgen deprivation therapy
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- PSMA: prostate-specific membrane antigen
- RT: radiotherapy

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 11 | Titles free |
| Detailed analysis | 13 sections | Paid |
| Verified statements with short source quotes and links | 218 | Paid |
| Who said each statement: the cited speakers | 14 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 11 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 13 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 15 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 11 of the 14 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

14 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Radiographic Progression-Free Survival (rPFS) Assessed by Investigator | discussed | 3 | 3 |
| Secondary endpoints | discussed | 2 | 2 |
| Population and setting | discussed | 8 | 4 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 7 | 5 |
| Safety and tolerability | discussed | 8 | 2 |
| Design and conduct | discussed | 7 | 4 |
| Biological rationale and uncertainty about clinical translation | discussed | 18 | 7 |
| Doublet versus chemotherapy-containing triplet selection | discussed | 29 | 4 |
| Disease-site heterogeneity, imaging and diagnostic certainty | discussed | 12 | 2 |
| Hormonal-partner choice, cardiovascular coordination and access | discussed | 26 | 4 |
| Genetic work-up, prognostic information and patient support | discussed | 23 | 8 |
| Prostate-directed radiation, urinary morbidity and referral timing | discussed | 14 | 3 |
| Downstream treatment applicability and aggressive progression | discussed | 13 | 3 |
| Implementation, uncommon monotherapy exceptions and cautious ADT interruption | discussed | 19 | 4 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 198 statements · 91%** | | | |
| YouTube | 11 | 1 | 1 |
| Podcasts | 187 | 4 | 4 |
| **Posts · 12 statements · 5%** | | | |
| X threads | 12 | 9 | 36 |
| **Primary sources · 8 statements · 4%** (cited for context, not screened) | | | |
| Registry (primary source, cited for context) | 8 | 1 | not screened |

- Screened window: 2022-09-10 to 2025-01-14
- Cited window: 2022-10-21 to 2024-09-16
- Retrieved: 2026-11-15

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
- Registry: NCT05288166 (https://clinicaltrials.gov/study/NCT05288166)
- Study IDs: 18448 · I3Y-MC-JPEG (Eli Lilly and Company) · 2022-500461-28-06 (EU Trial Number)
- Sponsor: Eli Lilly and Company
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 925 (actual)
- Start: 2022-04-14 (actual)
- Primary completion: 2024-02-15 (actual)
- Primary endpoint: Radiographic Progression-Free Survival (rPFS) Assessed by Investigator (From Date of Randomization to Radiographic Disease Progression or Death from Any Cause (up to 22 months))
- Intervention: Abemaciclib (drug)
- Intervention: Abiraterone (drug)
- Intervention: Prednisone or Prednisolone (drug)
- Intervention: Placebo for Abemaciclib (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- For 2 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- Not yet captured in this edition: a view on occupational cognitive demands as a reason to consider alternatives to first-line enzalutamide; a remark on abemaciclib’s mechanism and investigational status in metastatic hormone-sensitive prostate cancer; a view on metastasis-directed treatment, systemic therapy deferral, and uncertainty about safely stopping systemic treatment; a view on selecting patients for triplet therapy rather than standard doublet treatment in metastatic hormone-sensitive prostate cancer; a remark on selected-patient triplet evidence and continuing therapeutic need in high-risk metastatic hormone-sensitive prostate cancer; a question about de novo metastatic representation in evidence informing treatment intensification; a view on PSMA-targeted radioligand therapy as an emerging systemic option in metastatic hormone-sensitive prostate cancer; a view on cautious treatment interruption in hormone-sensitive disease because of comorbidities or severe side effects.
- 1 more clinician view in the sources used in this report is not yet captured as evidence in this edition.
- 126 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 30 sources about other trials or topics are not included.
- ClinicalTrials.gov first posted results for CYCLONE 3 on 27 June 2025. The cited commentary dates from October 2022 to September 2024 and predates those results; none of it discusses them. No separate results publication was identified in the sources reviewed for this edition. Protocol objectives and endpoints, and expectations expressed before that posting, must not be read as observed benefit or harm.
- The public discussion located through trial names and identifiers may miss relevant unnamed discussion or differently transcribed references. The report does not represent all HCPs or all public discussion.
- Individual ownership is uncertain for many podcast and video passages. Participation lists, program descriptions and familiar speaker labels do not establish who said those words.
- Several episodes may include overlapping participants, and reposts or quoted posts do not establish additional independent HCP opinions.
- Treatment preferences, approval statements, reimbursement experiences and guideline interpretations are historical as expressed in the sources, rather than current clinical or regulatory guidance.
- Protocol and commentary descriptions differ on some eligibility and design details. Spoken thresholds and prior-docetaxel descriptions are preserved as statements, not silently substituted for the protocol.
- Broader mHSPC practice discussions often include populations, alternatives or later treatment consequences not directly tested by CYCLONE 3; they do not establish abemaciclib benefit in a subgroup.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-17 UTC: current edition
  - Routine maintenance: 1 fix (tags):
    - 2026-11-17 UTC: taxonomy mapping corrected

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-17 UTC. No changes.

## Offer

- Size: Standard · 218 verified statements · 54 from 11 confirmed clinicians
- Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $2,200
- 6 months of updates: $3,100
- 12 months of updates: $4,400
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (13 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/cyclone-3-nct05288166
- Agents: POST https://www.erudio.com/api/orders with {"report": "cyclone-3-nct05288166", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=cyclone-3-nct05288166

## Cite

Erudio Health. CYCLONE 3 (NCT05288166): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 17, 2026. https://www.erudio.com/reports/cyclone-3-nct05288166

## Questions

### How much does the CYCLONE 3 report cost?

One edition costs $1,250 (Standard · 218 verified statements · 54 from 11 confirmed clinicians). With updates: 3 months $2,200, 6 months $3,100, 12 months $4,400. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the CYCLONE 3 report cover?

218 statements from 15 sources (4 podcasts, 1 video, 9 posts, 1 registry record), 54 of them from 11 confirmed clinicians, each linked to its source. Commentary checked Nov 17, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the CYCLONE 3 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "cyclone-3-nct05288166" }) previews it and create_order({ "report": "cyclone-3-nct05288166", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the CYCLONE 3 report?

Edition 1 (version 1.0.0), accepted Nov 17, 2026 UTC; last checked for new commentary Nov 17, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/cyclone-3-nct05288166.json
- Markdown: https://www.erudio.com/reports/cyclone-3-nct05288166.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/cyclone-3-nct05288166/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "cyclone-3-nct05288166"}`
